Comparison · NCT00845026-7a6682bc
LY2140023 vs Standard-of-Care (SOC): Number of Participants With Potentially Clinical Significant Change in Fasting Glucose Level
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. LY2140023 vs Standard-of-Care (SOC): Number of Participants With Potentially Clinical Significant Change in Fasting Glucose Level. Trial comparisons, record NCT00845026-7a6682bc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00845026-7a6682bc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.113 | 0.0582 | 0.207 | wilson | |
| Risk in group 2 | 0.167 | 0.1 | 0.265 | wilson | |
| Risk difference, group 1 minus group 2 | -0.054 | -0.166 | 0.0614 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.676 | 0.298 | 1.53 | log | |
| Odds ratio, group 1 over group 2 | 0.635 | 0.246 | 1.64 | log | |
| Number needed to treat, for one fewer participant with the outcome on LY2140023 than on Standard-of-Care (SOC) | 18.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | LY2140023 | 80 mg, oral tablets, twice daily: 40 mg in the morning, 40 mg in the evening, for 24 weeks. The dose may be adjusted to a minimum of 40 mg or a maximum of 160 mg. | 8 | 71 | OG000 |
| Group 2 | Standard-of-Care (SOC) | aripiprazole: 10 mg, oral tablets, once a day in the evening for three days. Followed by a dose increase to 20 mg, 2-10 mg oral tablets, once a day in the evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 30 mg (3-10 mg oral tablets).~olanzapine: 10 mg dose (2-5 mg oral tablets) once every evening, for 3 days. Followed by an increase to 15 mg (3-5 mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10 mg or a maximum of 20 mg (4-5 mg oral tablets).~risperidone: 2 mg dose, 2-1 mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4 mg (4-1 mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2 mg/day or a maximum of 6 mg/day (6-1 mg tablets). | 13 | 78 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Potentially Clinical Significant Change in Fasting Glucose Level
- Description
Treatment-emergent changes in lab results on fasting glucose were analyzed using the American Diabetes Association (ADA 2001) and National Cholesterol Education Program (NCEP ATP III) guidelines. Glucose Normal to High is \<100 milligram/deciliter (mg/dL) at baseline and ≥126mg/dL post-baseline.
- Time frame
- Baseline through 52 weeks
- Population
- All randomized participants with a normal baseline and at least one post-baseline result.
Source ClinicalTrials.gov
Trial
- Title
- A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
- NCT number
- NCT00845026
- Phases
- PHASE2
- Conditions
- Schizophrenia
- Interventions
- LY2140023, aripiprazole, olanzapine, risperidone
- Lead sponsor
- Denovo Biopharma LLC
- Results first posted
- 2022-09-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00845026?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00845026-7a6682bc